TaiMed Biologics (4147) — Long-term Investment Intensity
TaiMed Biologics (4147) has a Long-term Investment Intensity of 5.3% as of December 2019. Long-term investments of NT$249.36 Million represent 5.3% of total assets of NT$4.73 Billion. A higher ratio indicates a company with significant capital committed to long-duration strategic positions. Check cash flow reinvestment rate of TaiMed Biologics to assess the company's total reinvestment commitment from operating cash flow.
LT Investment Intensity
Long-term Investments
Total Assets
Country
TaiMed Biologics Long-term Investment Intensity (2016–2019)
This chart shows how TaiMed Biologics's Long-term Investment Intensity has evolved across 4 annual periods from 2016 to 2019. As of December 2019, the intensity stands at 5.3%, reflecting long-term investments of NT$249.36 Million against total assets of NT$4.73 Billion TWD. Explore TaiMed Biologics (4147) cash flow to debt to assess how comfortably operating cash covers total debt obligations.
Annual Long-term Investment Intensity for TaiMed Biologics (2016–2019)
The table below presents the year-by-year Long-term Investment Intensity for TaiMed Biologics from 2016 to 2019, covering 4 annual filings. Each row shows total assets, long-term investments, the intensity percentage, and the change in percentage points compared to the prior year. For market capitalisation and broader financial context, see 4147 company net worth.
| Year | LT Investment Intensity | LT Investments (TWD) | Total Assets | Change (pp) |
|---|---|---|---|---|
| 2019 | 5.3% | NT$249.36 Million | NT$4.73 Billion | ▼ -4.4 pp |
| 2018 | 9.7% | NT$462.53 Million | NT$4.79 Billion | ▲ +6.0 pp |
| 2017 | 3.6% | NT$164.25 Million | NT$4.50 Billion | ▲ +3.4 pp |
| 2016 | 0.2% | NT$10.00 Million | NT$4.80 Billion | — |